# Study of OB-002 in Patients With Refractory Metastatic Cancer

> **NCT05940844** · PHASE1 · WITHDRAWN · sponsor: **Orion Biotechnology Polska Sp. z o.o.**

## Conditions studied

- Metastatic Cancer
- Metastatic Colorectal Cancer
- Metastatic Pancreatic Cancer
- Metastatic Gastric Cancer
- Metastatic Breast Cancer
- Metastatic Urothelial Carcinoma

## Interventions

- **DRUG:** OB-002

## Key facts

- **NCT ID:** NCT05940844
- **Lead sponsor:** Orion Biotechnology Polska Sp. z o.o.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2024-01
- **Primary completion:** 2025-04
- **Final completion:** 2025-08
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** study terminated due to changes in the drug development plan
- **Last updated:** 2025-04-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05940844

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05940844, "Study of OB-002 in Patients With Refractory Metastatic Cancer". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT05940844. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*